Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases and cancer.

Revenue(FY, 2017)

$2.5 B

Market capitalization(2018-06-22)

$40.6 B

Type

Public

Boston, US

Founded

1989

Size (employees)

2,300 (est)+7%

Website

vrtx.com

Vertex Pharmaceuticals was founded in 1989 and is headquartered in Boston, US

Report incorrect company information

Key People/Management at Vertex Pharmaceuticals

Jeffrey Leiden

Chairman, President and CEO

David Altshuler

Executive Vice President, Global Research and Chief Scientific Officer

Stuart Arbuckle

Executive Vice President and Chief Commercial Officer

Reshma Kewalramani

Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer

Michael Parini

Executive Vice President, Chief Legal and Administrative Officer

Amit Sachdev

Executive Vice President and Chief Regulatory Officer

Report incorrect company information

Vertex Pharmaceuticals Office Locations

Vertex Pharmaceuticals has an office in Boston

Boston, US (HQ)

50 Northern Ave

Show all (1)

Report incorrect company information

Vertex Pharmaceuticals Financials and Metrics

Vertex Pharmaceuticals Financials

Vertex Pharmaceuticals's revenue was reported to be $2.49 b in FY, 2017

Summary

USD
Revenue (Q1, 2018)	640.8 m
Gross profit (Q1, 2018)	569.2 m
Gross profit margin (Q1, 2018), %	88.8%
Net income (Q1, 2018)	227.3 m
EBIT (Q1, 2018)	128.9 m
Market capitalization (22-Jun-2018)	40.6 b
Closing share price (22-Jun-2018)	159.2
Cash (31-Mar-2018)	2 b

Vertex Pharmaceuticals's current market capitalization is $40.6 b.

Income Statement

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Revenue	1.2 b	580.4 m	1 b	1.7 b	2.5 b
Revenue growth, %		(52%)	78%	65%
R&D expense				1 b	1.3 b
Operating expense total				1 b	2.4 b

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q1, 2018
Revenue	221.7 m	118.5 m	138.4 m	179 m	138.5 m	166.1 m	309.8 m	398.1 m	431.6 m	413.8 m	714.7 m	544.1 m	640.8 m
Cost of goods sold													71.6 m
Gross profit													569.2 m
Gross profit Margin, %													89%

show all

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cash	569.3 m	625.3 m	714.8 m	1.2 b	1.7 b
Accounts Receivable	85.5 m	76 m	177.6 m	201.1 m	281.3 m
Inventories	14.1 m	30.8 m	57.2 m	77.6 m	111.8 m
Current Assets	1.6 b	1.5 b	1.4 b	1.8 b	2.6 b

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q1, 2018
Cash	583.2 m	424 m	420.6 m	718.6 m	664.9 m	870.5 m	756.3 m	604.2 m	605.9 m	719.7 m	1 b	1.2 b	2 b
Accounts Receivable	120.3 m	59.9 m	81.8 m	114.3 m	80.3 m	94.5 m	165.3 m	181.9 m	189.4 m	182.2 m	208 m	247.9 m	327.3 m
Inventories	13.5 m	11.3 m	12 m	16.8 m	34.1 m	42.1 m	49.2 m	63.2 m	66.6 m	71.8 m	82 m	92.3 m	117.3 m
Current Assets	1.6 b	1.4 b	1.3 b	1.7 b	1.4 b	1.3 b	1.4 b	1.4 b	1.5 b	1.5 b	1.9 b	2.2 b	3 b

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Net Income	(687.6 m)	(742.7 m)	(588.2 m)	(84 m)	91.6 m
Depreciation and Amortization	48.4 m	63.3 m	62.3 m	61.4 m	61.4 m
Inventories	7.1 m	(16 m)	(23 m)	(16.5 m)	(45 m)
Accounts Payable	(49.2 m)	25 m	(1.7 m)	(11.7 m)	8.8 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q1, 2018
Net Income	(128.7 m)	(232.5 m)	(159.4 m)	(198.7 m)	(391.8 m)	(561.9 m)	(36.1 m)	(72.3 m)	(111.8 m)	249.5 m	(72.3 m)	227.3 m
Depreciation and Amortization							16.4 m	31.4 m	45.9 m	14.9 m		16.3 m
Inventories					42.1 m	49.2 m	(4.8 m)	(7.8 m)	(11.5 m)	(3.7 m)		(8.2 m)
Accounts Payable					72.7 m	78.9 m	(343 k)	(23.8 m)	(21.5 m)	717 k		2.2 m